REG - AstraZeneca PLC - Director/PDMR Shareholding

AstraZenecaAnnouncement

04/12/2018 15:00

RNS Number : 4225J
AstraZeneca PLC
04 December 2018
 


4 December 2018 15:00 GMT
 
TRANSACTION BY PERSON DISCHARGING MANAGERIAL RESPONSIBILITIES
 
AstraZeneca PLC (the Company) announces that, on 3 December 2018, Marc Dunoyer, a person discharging managerial responsibilities (PDMR) exercised an option to purchase 544 of the Company's ordinary shares of $0.25 each (Ordinary Shares) at a price of £33.07 per Ordinary Share, under the AstraZeneca PLC 2012 Savings Related Share Option Scheme (Sharesave).
 
Further details are set out in the attached notification, made in accordance with the requirements of the EU Market Abuse Regulation.
 



1
 


Details of the person discharging managerial responsibilities / person closely associated
 




a)
 


Name
 
 


Marc Dunoyer




2
 


Reason for the notification
 




a)
 


Position/status
 
 


Chief Financial Officer




b)
 


Initial notification /Amendment
 
 


Initial notification




3
 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 




a)
 


Name
 
 


AstraZeneca PLC




b)
 


LEI
 
 


PY6ZZQWO2IZFZC3IOL08




4
 


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
 
 




a)
 


Description of the financial instrument, type of instrument
 
Identification code
 
 


Ordinary Shares of US$0.25 each in AstraZeneca PLC
 
 
GB0009895292
 




b)
 


Nature of the transaction
 
 


Exercise of option to purchase shares under the AstraZeneca PLC 2012 Savings Related Share Option Scheme (Sharesave)




c)
 


Price(s) and volume(s)
 
 


 



Price(s)
 


Volume(s)




£33.07
 


544
 



 
 




d)
 


Aggregated information
 
 
- Aggregated volume
 
 
- Price
 
 


Not applicable - single transaction
 
 
 
 
 
 
 




e)
 


Date of the transaction
 
 


3 December 2018




f)
 


Place of the transaction
 
 


Outside a trading venue



 
 
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. 
 
For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.
 
 



Media Relations












Karen Birmingham


UK/Global


+44 203 749 5634




Rob Skelding


UK/Global


+44 203 749 5821




Matt Kent


UK/Global


+44 203 749 5906




Gonzalo Viña


UK/Global


+44 203 749 5916




Jennifer Hursit


UK/Global


+44 7384 799 726




Jacob Lund


Sweden


+46 8 553 260 20




Michele Meixell


US


+1 302 885 2677


















Investor Relations












Thomas Kudsk Larsen






+44 203 749 5712




Henry Wheeler


Oncology


+44 203 749 5797




Christer Gruvris


Cardiovascular; Metabolism


+44 203 749 5711




Nick Stone


Respiratory; Renal


+44 203 749 5716




Josie Afolabi


Other


+44 203 749 5631




Craig Marks


Finance; Fixed Income


+44 7881 615 764




Jennifer Kretzmann


Retail Investors


+44 203 749 5824




US toll-free






+1 866 381 7277

















Adrian Kemp

Company Secretary
AstraZeneca PLC
 
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHUSSSRWAAURAA